Impact of presymptomatic genetic testing for familial amyotrophic lateral sclerosis
- PMID: 21285887
- PMCID: PMC4039017
- DOI: 10.1097/GIM.0b013e318204d004
Impact of presymptomatic genetic testing for familial amyotrophic lateral sclerosis
Abstract
Purpose: The Pre-familial Amyotrophic Lateral Sclerosis (Pre-fALS) study is a longitudinal study of individuals potentially at risk for developing familial amyotrophic lateral sclerosis. Our goals were to (1) explore participants' decisions of whether to learn results of presymptomatic testing or not; (2) understand the psychosocial impact of these decisions; and (3) assess preferences for receiving results by telephone or in person.
Methods: The sample for this substudy comprised 20 participants drawn randomly from autosomal dominant mutant superoxide dismutase 1 families in the Pre-fALS study. Twenty participants completed a semistructured phone interview; prominent themes were identified and rated.
Results: Fourteen participants chose to learn results; six had mutant superoxide dismutase 1 and eight had wild-type superoxide dismutase 1. Of the six who initially elected nondisclosure, three were reconsidering their decision. Regardless of the results and method of counseling, participants had adapted well, at least in the short term.
Conclusion: We recommend that (1) those considering presymptomatic genetic testing should undergo professional counseling to help decide whether to learn results; (2) discussion should include the option of telephone genetic counseling for those without easy access to in-person counseling; and (3) those who initially decline to learn results should be offered the opportunity to learn their mutation status as their decision evolves.
Similar articles
-
Presymptomatic ALS genetic counseling and testing: Experience and recommendations.Neurology. 2016 Jun 14;86(24):2295-302. doi: 10.1212/WNL.0000000000002773. Epub 2016 May 18. Neurology. 2016. PMID: 27194384 Free PMC article. Review.
-
"You have shown me my end": attitudes toward presymptomatic testing for familial amyotrophic lateral sclerosis.Am J Med Genet A. 2004 Sep 1;129A(3):248-53. doi: 10.1002/ajmg.a.30178. Am J Med Genet A. 2004. PMID: 15326623
-
How the prospect of a clinical trial impacts decision-making for predictive genetic testing in ALS.Amyotroph Lateral Scler Frontotemporal Degener. 2025 May;26(3-4):343-351. doi: 10.1080/21678421.2024.2423718. Epub 2024 Nov 7. Amyotroph Lateral Scler Frontotemporal Degener. 2025. PMID: 39511709
-
Absence of linkage between familial amyotrophic lateral sclerosis and copper chaperone for the superoxide dismutase gene locus in two Italian pedigrees.Neurosci Lett. 2000 May 12;285(2):83-6. doi: 10.1016/s0304-3940(00)01032-6. Neurosci Lett. 2000. PMID: 10793232
-
Amyotrophic lateral sclerosis: copper/zinc superoxide dismutase (SOD1) gene mutations.Neuromuscul Disord. 2000 Jan;10(1):63-8. doi: 10.1016/s0960-8966(99)00071-1. Neuromuscul Disord. 2000. PMID: 10677867 Review.
Cited by
-
Presymptomatic ALS genetic counseling and testing: Experience and recommendations.Neurology. 2016 Jun 14;86(24):2295-302. doi: 10.1212/WNL.0000000000002773. Epub 2016 May 18. Neurology. 2016. PMID: 27194384 Free PMC article. Review.
-
"What does it mean?": uncertainties in understanding results of chromosomal microarray testing.Genet Med. 2012 Feb;14(2):250-8. doi: 10.1038/gim.2011.52. Epub 2012 Jan 5. Genet Med. 2012. PMID: 22241091 Free PMC article.
-
Genetic testing for monogenic forms of motor neuron disease/amyotrophic lateral sclerosis in unaffected family members.Eur J Hum Genet. 2025 Jan;33(1):7-13. doi: 10.1038/s41431-024-01718-4. Epub 2024 Nov 5. Eur J Hum Genet. 2025. PMID: 39501102 Free PMC article. Review.
-
Preventing amyotrophic lateral sclerosis: insights from pre-symptomatic neurodegenerative diseases.Brain. 2022 Mar 29;145(1):27-44. doi: 10.1093/brain/awab404. Brain. 2022. PMID: 34677606 Free PMC article.
-
Fluctuating salience in those living with genetic risk of motor neuron disease: A qualitative interview study.Health Expect. 2024 Apr;27(2):e14024. doi: 10.1111/hex.14024. Health Expect. 2024. PMID: 38528673 Free PMC article.
References
-
- Haverkamp LJ, Appel V, Appel SH. Natural history of amyotrophic lateral sclerosis in a database population. Validation of a scoring system and a model for survival prediction. Brain. 1995;118(Pt 3):707–719. - PubMed
-
- Chio A, Traynor BJ, Lombardo F, et al. Prevalence of SOD1 mutations in the Italian ALS population. Neurology. 2008;70:533–537. - PubMed
-
- Andersen P, Nilsson P, Keranen M, et al. Phenotypic heterogeneity in motor neuron disease patients with CuZn superoxide dismutase mutations in Scandinavia. Brain. 1997;120:1723–1737. - PubMed
-
- Boukaftane Y, Khoris J, Moulard B, et al. Identification of six novel SOD1 gene mutations in familial amyotrophic lateral sclerosis. Can J Neurol Sci. 1998;25:192–196. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous